TY - JOUR
T1 - Waning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020
T2 - A 12-month-evaluation in three population-based European studies
AU - Novelli, Sophie
AU - Reinkemeyer, Christina
AU - Bulaev, Dmitry
AU - O'Sullivan, Marc Paul
AU - Snoeck, Chantal J
AU - Rauschenberger, Armin
AU - Manto, Carmelite
AU - Kolodkin, Alexey
AU - Ghosh, Soumyabrata
AU - Satagopam, Venkata
AU - le Chenadec, Jerome
AU - Barthelemy, Karine
AU - Priet, Stephane
AU - de Lamballerie, Xavier
AU - Wieser, Andreas
AU - Kroidl, Inge
AU - Vaillant, Michel
AU - Meyer, Laurence
AU - Hoelscher, Michael
AU - Castelletti, Noemi
AU - Krüger, Rejko
AU - Warszawski, Josiane
AU - ORCHESTRA working group
N1 - Funding:
This project has received funding from the European Union’s Horizon 2020
research and innovation program under grant agreement No 101016167, ORCHESTRA (Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic. The views expressed in this paper are the sole responsibility of the authors and the Commission is not responsible for any
use that may be made of the information it contains.
The KoCo19 study has received funding from the Bavarian State Ministry of Science and the Arts, University Hospital, LMU Munich, Helmholtz Centre Munich, University of Bonn, University of Bielefeld, German Ministry for
Education and Research (Project number: 01KI20271 and others). Euroimmun and Roche provided kits and machines for analyses at discounted rates for the study. The EpiCov cohort was supported by research grants from Inserm
(Institut National de la Santé et de la Recherche Médicale), the French Ministry for Research, Drees-Direction de la Recherche, des Etudes, de l’Evaluation et des Statistiques, and the French Ministry for Health and by the Région Ile-de-France. The CON-VINCE Study was funded by the National Research Fund Luxembourg
(14716281/ CONVINCE/ Kruger) and the André Losch Foundation (Luxembourg). In addition, A.W. and M.H. report personal fees and non-financial support from Roche Diagnostics.
A.W. and M.H. report non-financial support from Euroimmun, non-financial support from Viramed, non-financial support from Mikrogen.
A.W. and M.H. report grants, non-financial support and other from German Centre for Infection Research DZIF, grants and non-financial support from Government of Bavaria, non-financial support from BMW, non-financial
support from Munich Police, nonfinancial support and other from Accenture. A.W. and M.H. report personal fees and nonfinancial support from Dr. Box-Betrobox, non-financial support from Dr. Becker MVZ during the conduct of the
study. A.W. is involved in other different patents and companies not in relation to the serology of SARS-CoV-2. A.W. reports personal fees and others from Haeraeus Sensors, nonfinancial support from Bruker Daltonics, all of which are
outside the submitted work, and non-srelated to SARS-CoV-2. The funders provided support in the form of salaries for authors, but did not have any additional role in the study design, data collection and analysis, decision to
publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
Copyright: © 2025 Novelli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2025/5/9
Y1 - 2025/5/9
N2 - OBJECTIVES: We described waning in anti-SARS-CoV-2 IgG in adult general populations infected during the first wave of the COVID-19 pandemic in 2020 across three European countries.METHODS: Coordinated analyses were conducted separately in three population-based cohorts with complementary follow-up schedules: the KoCo19 (Germany), EpiCov (France), and CON-VINCE (Luxembourg) cohorts. Serological follow-up was based on the anti-SARS-CoV-2 ELISA-S IgG (Euroimmun) assay. We selected all adults aged 18-79 who had a positive serology (IgG optical density (OD) ratio ≥1.1) between February and July 2020, and at least one subsequent IgG measurement within the following 12 months, while still non-vaccinated.RESULTS: The proportion of seroreversion was 0% within the four first months, based on Koco19 data (n = 65 participants). In the longer term, 31.3% of participants had seroreverted at 6 months (95%CI: 24.4-39.1) (based on EpiCov data, n = 599), 31.3% (95%CI: 11.0-58.7) at 12 months (based on CON-VINCE data, n = 16). From EpiCov data, both baseline low IgG levels and seroneutralization negativity remained predictive of seroreversion in multivariable analysis.CONCLUSION: From population-based cohorts, anti-S IgG levels remained stable during the first 4 months following SARS-CoV-2 infection. Most of the decay occurred afterward; nearly one-third of people seroreverted 6 and 12 months later. Low IgG levels and seroneutralization negativity were independent predictors of seroreversion.
AB - OBJECTIVES: We described waning in anti-SARS-CoV-2 IgG in adult general populations infected during the first wave of the COVID-19 pandemic in 2020 across three European countries.METHODS: Coordinated analyses were conducted separately in three population-based cohorts with complementary follow-up schedules: the KoCo19 (Germany), EpiCov (France), and CON-VINCE (Luxembourg) cohorts. Serological follow-up was based on the anti-SARS-CoV-2 ELISA-S IgG (Euroimmun) assay. We selected all adults aged 18-79 who had a positive serology (IgG optical density (OD) ratio ≥1.1) between February and July 2020, and at least one subsequent IgG measurement within the following 12 months, while still non-vaccinated.RESULTS: The proportion of seroreversion was 0% within the four first months, based on Koco19 data (n = 65 participants). In the longer term, 31.3% of participants had seroreverted at 6 months (95%CI: 24.4-39.1) (based on EpiCov data, n = 599), 31.3% (95%CI: 11.0-58.7) at 12 months (based on CON-VINCE data, n = 16). From EpiCov data, both baseline low IgG levels and seroneutralization negativity remained predictive of seroreversion in multivariable analysis.CONCLUSION: From population-based cohorts, anti-S IgG levels remained stable during the first 4 months following SARS-CoV-2 infection. Most of the decay occurred afterward; nearly one-third of people seroreverted 6 and 12 months later. Low IgG levels and seroneutralization negativity were independent predictors of seroreversion.
KW - Humans
KW - COVID-19/epidemiology
KW - Middle Aged
KW - Adult
KW - Antibodies, Viral/blood
KW - Female
KW - Male
KW - SARS-CoV-2/immunology
KW - Immunoglobulin G/blood
KW - Aged
KW - Adolescent
KW - Young Adult
KW - Europe/epidemiology
KW - Pandemics
UR - https://pubmed.ncbi.nlm.nih.gov/40344145/
U2 - 10.1371/journal.pone.0320196
DO - 10.1371/journal.pone.0320196
M3 - Article
C2 - 40344145
SN - 1932-6203
VL - 20
JO - PLoS ONE
JF - PLoS ONE
IS - 5
M1 - e0320196
ER -